A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
复制标题
DOI：
10.1038/sj.bjc.6601724
复制
发表时间：
2004-04-05
影响因子：
8.8
通讯作者：
Kim, HT
中科院分区：
文献类型：
--
作者：
Park, YH;Ryoo, BY;Kim, HT
卡培他滨和多西紫杉醇对胃癌有相当大的单药活性，作用机制不同，关键毒性没有重叠。这两种药物之间的协同作用是通过紫杉烷诱导胸苷磷酸化酶上调而介导的。我们研究了卡培他滨和多西紫杉醇联合化疗在未经治疗的进展期胃癌(AGC)患者中的有效性和可行性。2001年9月至2003年3月，42例AGC患者接受卡培他滨(1250 mg m(-2)，每日2次，第1~14天)和多西紫杉醇(75 mg m(-2))静脉注射，21天为一个周期。在第一天)。这些患者总共接受了164个周期的化疗。中位年龄53.5岁(33~73岁)。在38名可评估疗效的患者中，总有效率为60%(95%可信区间，45%-74%)。中位无进展生存期为5.2个月(1.0~15+月)，中位总生存期为10.5个月(2.9~23.7+个月)。最常见的3/4级不良事件是手足综合征(HFS：G3 50%)、中性粒细胞减少症(15%)和白细胞减少症(12%)。这种组合的进一步研究显然是有必要的，尽管这两种药物的剂量都较小(1000 mg m(-2)，每天两次，60 mg m(-2))，以减少HFS和甲裂的发生率。
Capecitabine and docetaxel have considerable single-agent activity in gastric cancer with distinct mechanisms of action and no overlap of key toxicities. A synergistic interaction between these two drugs is mediated by taxane-induced upregulation of thymidine phosphorylase. We investigated the activity and the feasibility of capecitabine and docetaxel combination chemotherapy in patients with previously untreated advanced gastric cancer (AGC). From September 2001 to March 2003, 42 patients with AGC received 21-day cycles of oral capecitabine (1250 mg m(-2) twice daily on days 1-14) and docetaxel (75 mg m(-2) i.v. on day 1). The patients received a total of 164 cycles of chemotherapy. The median age was 53.5 years (range 33-73 years). The overall response rate in the 38 efficacy-evaluable patients was 60% (95% confidence interval, 45-74%). The median progression-free survival was 5.2 months (range, 1.0-15 + months) and the median overall survival was 10.5 months (range, 2.9-23.7 + months). The most common grade 3/4 adverse events were hand-foot syndrome (HFS: G3 50%), neutropenia (15%) and leucopenia (12%). Further studies of this combination are clearly warranted, albeit with lower doses of both agents (1000 mg m(-2) twice daily and 60 mg m(-2)) to reduce the rate of HFS and onycholysis.